Analysts Set Kailera Therapeutics, Inc. (NASDAQ:KLRA) PT at $42.75

Kailera Therapeutics, Inc. (NASDAQ:KLRA) has earned an average recommendation of “Moderate Buy” from the eight analysts that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $42.75.

KLRA has been the topic of a number of research reports. Weiss Ratings started coverage on shares of Kailera Therapeutics in a report on Friday, August 14th. They issued a “sell (d)” rating on the stock. Wall Street Zen lowered shares of Kailera Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 30th.

Kailera Therapeutics Stock Performance

KLRA stock opened at $12.83 on Monday. The firm has a market cap of $1.66 billion and a P/E ratio of -0.00. Kailera Therapeutics has a fifty-two week low of $12.36 and a fifty-two week high of $28.23. The business’s 50 day moving average price is $17.03.

Kailera Therapeutics (NASDAQ:KLRA) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.35). Equities analysts predict that Kailera Therapeutics will post -3.89 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Tidal Investments LLC purchased a new position in shares of Kailera Therapeutics during the 2nd quarter worth $309,000. Squarepoint Ops LLC purchased a new position in shares of Kailera Therapeutics during the 2nd quarter worth about $993,000. Frazier Life Sciences Management L.P. bought a new position in Kailera Therapeutics in the 2nd quarter valued at $24,233,000. Wellington Management Group LLP purchased a new position in shares of Kailera Therapeutics during the second quarter worth approximately $64,308,000. Finally, Atlas Venture Life Science Advisors LLC bought a new position in shares of Kailera Therapeutics during the 2nd quarter worth $113,923,000.

Kailera Therapeutics Company Profile

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and related metabolic diseases. The company’s programs are designed to address the substantial medical needs associated with excess weight and metabolic disorders.

Kailera’s lead product candidate is KAIL-001, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist intended for the treatment of obesity and potentially related conditions. The company is advancing its pipeline through clinical development and regulatory activities, although its products remain investigational and are not yet approved for commercial use.

The company’s operations are centered on the development of therapies for global markets.